A You Tube video of the announcement by Dr. Joe Galati is posted, discussing how Liver Specialists of Texas will evaluate and treat both new and old patients with Boceprevir. After years of research, and great anticipation by patients and physicians involved in the care of patients with hepatitis C, Boceprevier was finially approved yesterday. Yesterday was a very important day for those of us involved in the care of patients with hepatitis C, as well as the millions of individuals affected by it. I received word yesterday afternoon that the FDA has approved boceprevir for the treatment of G1 CHC in previously untreated patients and patients who have failed previous interferon and ribavirin therapy. Boceprevir is the first in class direct acting antiviral to be FDA approved for CHC. Manufactured by Merck pharmaceutical company, the ...
- News & Media
- Dr. Galati's Book